TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Chugai Pharmaceutical Co ( (JP:4519) ) just unveiled an update.
Chugai Pharmaceutical Co., Ltd. announced that Eli Lilly’s investigational oral GLP-1 receptor agonist, orforglipron, showed positive results in the Phase 3 ATTAIN-2 trial for adults with obesity or overweight and type 2 diabetes. The trial demonstrated significant weight loss, HbA1c reduction, and improvements in cardiometabolic risk factors, with a safety profile consistent with existing GLP-1 medicines. This development is not expected to impact Chugai’s financial forecast for the fiscal year ending December 2025.
The most recent analyst rating on (JP:4519) stock is a Hold with a Yen6500.00 price target. To see the full list of analyst forecasts on Chugai Pharmaceutical Co stock, see the JP:4519 Stock Forecast page.
More about Chugai Pharmaceutical Co
Chugai Pharmaceutical Co., Ltd. operates in the pharmaceutical industry, focusing on the development and distribution of innovative medicines. The company is known for its contributions to oncology, immunology, and other therapeutic areas, primarily serving the Japanese market and collaborating with global partners.
Average Trading Volume: 2,760,647
Technical Sentiment Signal: Buy
Current Market Cap: Yen10210.9B
See more insights into 4519 stock on TipRanks’ Stock Analysis page.